伊美司他(端粒酶抑制剂)对正常与恶性巨核细胞生成的不同影响
本文利用体外巨核细胞生成体系研究伊美司他(GRN163L)导致血小板减少的机制及其对骨髓增殖性肿瘤(MPN)患者的治疗作用。结果显示,伊美司他仅延迟正常巨核细胞前体细胞成熟,而对MPN巨核细胞生成则影响多个阶段,减少可检测的巨核细胞集落形成单位并损害巨核细胞成熟;同时抑制恶性而非正常巨核细胞分泌纤维化生长因子。
要点
- 伊美司他仅延迟正常巨核细胞前体细胞成熟,这可解释其引起的血小板减少。
- 伊美司他对MPN巨核细胞生成影响更广泛,减少集落形成单位巨核细胞并损害成熟。
- 伊美司他抑制恶性而非正常巨核细胞分泌纤维化生长因子。
核心结论
- 正常巨核细胞成熟的延迟可能解释伊美司他引起的血小板减少,而伊美司他对MPN巨核细胞生成多个阶段的更广泛影响可能解释MPN患者中报告的有利临床结局。
研究设计与样本
- 采用成熟的体外巨核细胞生成体系,研究伊美司他(GRN163L)对正常与MPN巨核细胞生成的影响。
主要发现
- 伊美司他处理仅延迟正常巨核细胞前体细胞的成熟。
- 伊美司他影响MPN巨核细胞生成的额外阶段,导致可检测的集落形成单位巨核细胞数量减少并损害巨核细胞成熟。
- 伊美司他抑制恶性巨核细胞分泌纤维化生长因子,但不抑制正常巨核细胞分泌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imetelstat (GRN163L) is a specific telomerase inhibitor that has demonstrated clinical activity in patients with myeloproliferative neoplasms (MPN) and in patients with solid tumors. The antitumor effects were associated with the development of thrombocytopenia, one of the common side effects observed in patients treated with imetelstat. The events underlying these adverse effects are not apparent. In this report, we investigated the potential mechanisms that account for imetelstat's beneficial effects in MPN patients and the manner by which imetelstat treatment leads to a reduction in platelet numbers. Using a well-established system of ex vivo megakaryopoiesis, we demonstrated that imetelestat treatment affects normal megakaryocyte (MK) development by exclusively delaying maturation of MK precursor cells. By contrast, additional stages along MPN MK development were affected by imetelstat resulting in reduced numbers of assayable colony-forming unit MK and impaired MK maturation. In addition, treatment with imetelstat inhibited the secretion of fibrogenic growth factors by malignant but not by normal MK. Our results indicate that the delay observed in normal MK maturation may account for imetelstat-induced thrombocytopenia, while the more global effects of imetelstat on several stages along the hierarchy of MPN megakaryopoiesis may be responsible for the favorable clinical outcomes reported in MPN patients.
引用
- Mosoyan G, Kraus T, Ye F, et al. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Leukemia. 2017. PMID: 28270692. doi:10.1038/leu.2017.78
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。